Baker Bros. Advisors’s Talis Biomedical Corporation Common Stock TLIS Stock Holding History

Baker Bros. Advisors’s Portfolio TLIS Stock Details TLIS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-508,323	Closed	-$4.4M	–	98
2024 Q2	$4.4M	Hold	508,323	–	–	0.06%	69
2024 Q1	$4.45M	Hold	508,323	–	–	0.06%	64
2023 Q4	$3.79M	Hold	508,323	–	–	0.04%	65
2023 Q3	$2.93M	Buy	508,323 +1	+0%	+$7	0.02%	76
2023 Q2	$3.66M	Hold	508,322	–	–	0.02%	81
2023 Q1	$3.74M	Hold	508,322	–	–	0.02%	76
2022 Q4	$3.4M	Hold	508,322	–	–	0.02%	85
2022 Q3	$5.2M	Hold	508,322	–	–	0.03%	77
2022 Q2	$6.19M	Hold	508,322	–	–	0.04%	75
2022 Q1	$10.8M	Hold	508,322	–	–	0.06%	65
2021 Q4	$30.6M	Buy	508,322 +3,333	+0.7%	+$249K	0.15%	47
2021 Q3	$47.3M	Hold	504,989	–	–	0.21%	40
2021 Q2	$83.5M	Hold	504,989	–	–	0.37%	25
2021 Q1	$97.3M	Buy	+504,989	New	+$126M	0.42%	22

Other funds holding TLIS

BCM

BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return

SPIA

Steward Partners Investment Advisory New York $19.6B AUM 22.89% 1-Year Est. Return

Baker Bros. Advisors's TLIS Position: Q3 2024 in Review

Baker Bros. Advisors sold out of Talis Biomedical Corporation Common Stock (TLIS) in Q3 2024, closing a stake of 508,323 shares — an estimated $4.4M sold.

Baker Bros. Advisors first reported a position in TLIS in Q1 2021 and held it in 14 quarters. The position peaked at $97.3M in Q1 2021. 2 funds tracked by Wall St. Rank hold TLIS as of Q3 2024.

Baker Bros. Advisors reported no remaining Talis Biomedical Corporation Common Stock position as of Q3 2024 after selling out during the quarter.
Baker Bros. Advisors sold 508,323 Talis Biomedical Corporation Common Stock shares in Q3 2024, an estimated $4.4M.
Baker Bros. Advisors first reported a position in Talis Biomedical Corporation Common Stock in Q1 2021 and held it in 14 quarters.
Baker Bros. Advisors's Talis Biomedical Corporation Common Stock position peaked at $97.3M in Q1 2021.
2 funds tracked by Wall St. Rank held Talis Biomedical Corporation Common Stock as of Q3 2024.

Based on Baker Bros. Advisors's 13F filing for Q3 2024, filed 14 Nov 2024.